The amyloid hypothesis of Alzheimer's disease at 25 years
By D. Selkoe, John Hardy. EMBO Molecular Medicine, 2016
5,452 citations recorded by the source corpus.
Despite continuing debate about the amyloid β‐protein (or Aβ hypothesis, new lines of evidence from laboratories and clinics worldwide support the concept that an imbalance between production and clearance of Aβ42 and related Aβ peptides is a very early, often initiating factor in Alzheimer's disease (AD). Confirmation that presenilin is the catalytic site of γ‐secretase has provided a linchpin: all dominant mutations causing early‐onset AD occur either in the substrate (amyloid precursor protein, APP) or the protease (presenilin) of the reaction that generates Aβ. Duplication of the wild‐type APP gene in Down's syndrome leads to Aβ deposits in the teens, followed by microgliosis, astrocytosis, and neurofibrillary tangles typical of AD. Apolipoprotein E4, which predisposes to AD in > 40% of cases, has been found to impair Aβ clearance from the brain. Soluble oligomers of Aβ42 isolated from AD patients' brains can decrease synapse number, inhibit long‐term potentiation, and enhance long‐term synaptic depression in rodent hippocampus, and injecting them into healthy rats impairs memory. The human oligomers also induce hyperphosphorylation of tau at AD‐relevant epitopes and cause neuritic dystrophy in cultured neurons. Crossing human APP with human tau transgenic mice enhances tau‐positive neurotoxicity. In humans, new studies show that low cerebrospinal fluid (CSF) Aβ42 and amyloid‐PET positivity precede other AD manifestations by many years. Most importantly, recent trials of three different Aβ antibodies (solanezumab, crenezumab, and aducanumab) have suggested a slowing of cognitive decline in post hoc analyses of mild AD subjects. Although many factors contribute to AD pathogenesis, Aβ dyshomeostasis has emerged as the most extensively validated and compelling therapeutic target.
Subfields: Biological Psychiatry, Physiology, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/e96d222537bf925416d11dd4ae512c5d2a09290f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biological Psychiatry
In Physiology
- John Hardy
- C. Iadecola
- K. Viola
- Thomas Wisniewski
- Eleanor Drummond
- Oskar Hansson
- B. de Strooper
- V. Perry
In Psychiatry and Mental health
- C. Iadecola
- Eleanor Drummond
- Thomas Wisniewski
- Oskar Hansson
- C. Lane
- John Hardy
- Julie A. Schneider
- Bradley T. Hyman
Citations in the corpus
- Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019, neutral): “This hypothesis has been the leading model of AD pathogenesis since it was first proposed, although portions have been revised or supplemented over time (Musiek and Holtzman, 2015; Selkoe and Hardy, 2016).”
- A Deep Learning Approach for Automated Diagnosis and Multi-Class Classification of Alzheimer’s Disease Stages Using Resting-State fMRI and Residual Neural Networks (2019, background): “AD pathogenesis is believed to be triggered due to the overproduction of amyloid-β (A β ) [1, 2] and hyper phosphorylation of tau [3, 4] protein.”
- Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer’s disease patients (2017, neutral): “key players in the initiation and propagation of Alzheimer’s disease (AD) pathology [1].”
- APP mouse models for Alzheimer's disease preclinical studies (2017, positive): “The existence of familial mutations that directly affect A b production and influence AD risk is often cited as evidence that A b accumulation is central to AD pathogenesis (amyloid cascade hypothesis: Selkoe & Hardy, 2016).”
- Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis (2019, background): “Notably, oligomeric Aβ-42 has already been implicated to be of high relevance to the neuro-toxicity in the Alzheimer’s disease patients (Selkoe and Hardy, 2016).”
- The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade (2018, background): “dence that AD is a transmissible prion-like disease [5], experimental data support the idea that A Os may spread from cell-to-cell and brain region-toregion in a prion-like manner.”
- Atomic-resolution structure of a disease-relevant Aβ(1–42) amyloid fibril (2016, background): “(2015) Peptide dimer structure in an Aβ(1-42) fibril visualized with cryo-EM.”
- Alzheimer’s disease: experimental models and reality (2017, background): “These mice develop NFTs, neurodegeneration, atrophy and motor deficits.”